Medtronic stock heads into the open after a modest decline
Published on 09/21/2026 at 06:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Medtronic stock closed lower on the NYSE on September 18, 2026, with a modest percent decline in USD terms compared with the prior session. The move left the shares lagging a broader healthcare peer group and still some distance below the company’s recent 52-week high.
September 18, 2026 in numbers
Medtronic plc (ISIN IE00BTN1Y115, NYSE: MDT) ended trading on the NYSE on September 18, 2026, at a confirmed closing price in USD that reflected a clear, single digit percent loss versus the prior close for the same venue and currency. In that session, the shares traded within an intraday range whose low remained above the established 52-week floor, while the high stayed below the 52-week peak, keeping the close comfortably inside the documented 52-week band per NYSE quote data. Daily volume on September 18, 2026, reached a level consistent with the stock’s recent average turnover, indicating neither extreme buying nor selling pressure during the regular trading day.
Compared with a relevant US healthcare benchmark index on September 18, 2026, Medtronic’s percent decline was slightly larger, so the stock underperformed the sector that day in both price change and relative distance to the latest 52-week high. The closing level on September 18, 2026, remained below that recent 52-week high by a measurable margin in USD terms, underscoring that the shares have not yet revisited their top of the year’s trading range in the current month.
Today’s outlook for September 21, 2026
Today, attention around Medtronic centers on its ongoing exchange offer to split off at least 80.1% of MiniMed Group, the company’s former diabetes business. As MSN reported on September 20, 2026, Medtronic’s exchange offer allows shareholders to tender ordinary shares in return for MiniMed common stock at a discount, with the structure designed to distribute at least 80.1% of MiniMed shares while providing approximately 107.53 dollars of MiniMed stock for every 100 dollars of Medtronic shares tendered if the upper limit does not apply. This corporate action remains a key strategic step for Medtronic and could influence trading dynamics around the stock as investors assess the long term impact on the company’s portfolio and capital structure in today’s US session and in the days ahead.
